Prompt
Tirzepatide evidence brief
Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.
New to Amass? Connect Amass to Claude first
The prompt
Paste this into Claude
tirzepatideDRUG ASSET: tirzepatide
You have the Amass MCP connected (TrialCore + BiomedCore). Assemble a one-document EVIDENCE
BRIEF for this asset — citation-auditable, every figure traceable to an Amass record.
1. PIVOTAL TRIALS. Call search_amass_trialcore_records with:
query = the DRUG ASSET, phase = "PHASE3", interventionType = "DRUG"
Keep the registrational / outcomes trials. Build a table: NCT | Acronym | Indication |
Sponsor | Status | Enrollment | Start — every field verbatim from the record.
2. EFFICACY EVIDENCE. Call search_amass_biomedcore_records with:
query = the DRUG ASSET + key indication terms, minJournalQualityJufo = 2, isRetracted = false
For each pivotal finding write one CLAIM grounded in a specific abstract. Quote the numbers
(%, kg, HR, CI, P) VERBATIM from that abstract — never rounded, never recalled. Tag each claim
with PMID, journal, JuFo tier, citationCount.
3. CROSS-CORE PROVENANCE. For one pivotal trial, call get_amass_trialcore_record and read its
referencesBiomedCore links — show the trial record pointing at its own describing paper
(NCT ↔ PMID). This is the publication↔trial graph no raw registry exposes.
4. SAFETY. Include at least one safety signal from a JuFo>=2 abstract, with its verbatim effect
size — do not soften or omit it.
5. Assemble sections 1–4 as a formatted .docx evidence brief. Close with an AUDIT TRAIL listing
every Amass ID and PMID cited, and a scope note: figures are verbatim from Amass records as of
<date>; this is an evidence digest, not regulatory advice.Why not just ask the model?
Ask a plain model for "a tirzepatide evidence brief" and it produces a fluent document with invented trial IDs, mis-remembered effect sizes, and citations that don't resolve.
- Plain model: plausible NCTs, recalled (often wrong) effect sizes, unresolvable citations.
- Amass: real TrialCore records (every NCT, sponsor, status and enrollment verbatim) plus a JuFo-gated, non-retracted corpus — the −20.8-point weight difference (PMID 37840095), the −5 mmHg systolic drop (PMID 39551891), the 2.15 retinopathy odds ratio (PMID 40637847) — each copied from the abstract, and the SUMMIT trial linked straight to its paper (NCT04847557 → PMID 39551891).
Honest scope
An evidence digest, not a label, a systematic review, or regulatory advice. The trial table is the Phase-3 drug set Amass returns for the asset, not an exhaustive program census; the efficacy and safety claims are a grounded sample of the high-quality literature, not a meta-analysis. Every figure is verbatim from an Amass record as of the run date and traceable by the PMIDs and Amass IDs in the audit trail.
More from the library
Keep exploring
| Short name | Source id | Registry | Copy of |
|---|---|---|---|
| Acute, 50/75 mg vs placebo | NCT04072354 | ClinicalTrials.gov | |
| ↳ EUCTR2019-000470-36-BG | EU CTR | NCT04072354 | |
| Acute, 75/100 mg vs placebo | NCT04092686 | ClinicalTrials.gov |
Watchlist Monitor
Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.

Landscape Monitor
Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.
| kinase | kinase_family_chembl_leaf | small_molecule_tractability | protac_tractability |
|---|---|---|---|
| PLK1 | Other protein kinase PLK family | Advanced Clinical | predictive-only |
| WEE1 | Other protein kinase WEE family | Advanced Clinical | predictive-only |
| CDK1 | CMGC protein kinase CDK5 subfamily | Advanced Clinical | predictive-only |
Target prioritization matrix
A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.
Run it yourself
Connect Amass to Claude and paste the prompt.
The connector takes about a minute to add, then this workflow runs on your own inputs.
- Data
- No training on your data
- Hosting
- EU-hosted, enterprise
- Isolation
- Tenant-isolated by architecture
- Certification
- ISO 27001, SOC 2, NIS2: in motion